Skip to main content
Top
Published in: Endocrine 3/2020

Open Access 01-03-2020 | Bisoprolol | Endocrine imaging

Stumbling broke the spleen and unveiled pheochromocytoma, which in turn broke the heart

Authors: Shams Y-Hassan, Henrik Falhammar

Published in: Endocrine | Issue 3/2020

Login to get access

Excerpt

A 61-year-old woman presented with abdominal and severe chest pain after stumbling over a stone during jogging. The patient had type 2 diabetes mellitus treated with oral medications in addition to a 4–5 years history of episodes of palpitations, anxiety, and high blood pressure. Abdominal computed tomography (CT) revealed a bleeding left heterogenous adrenal tumor measuring 82 × 89 × 115 mm3, retroperitoneal bleeding, and ruptured spleen, which was literally broken into two pieces (Fig. 1a, b). Echocardiography revealed mid-apical left ventricular ballooning typical for takotsubo syndrome (TS) (Fig. 1c, d) with suspicion of left ventricular thrombus (LVT, white arrow). Cardiac magnetic resonance imaging confirmed TS with typical mid-apical ballooning pattern of the left ventricle complicated by LVT (Fig. 1e, f white arrows). Native T1 map shows signs of regional myocardial edema in the hypokinetic segments. On late gadolinium enhancement imaging, there was no signs of myocardial infarction. CT coronary angiography showed completely normal left and right coronary arteries. These findings were typical for TS complicated by LVT. The bleeding and rupture of the spleen was treated with embolization of the splenic artery. Marked elevation of both plasma metanephrine and normetanephrine (5.1 and 26 nmol/L, respectively; normal <0.3 and <1.1 nmol/L, respectively) was found. Consequently, stumbling during jogging caused splenic rupture and unmasked the pheochromocytoma, which in turn triggered broken heart syndrome or TS. Because the left ventricular wall motion abnormality in TS is completely reversible, supportive therapy in the form of beta-blockers (bisoprolol), but also alpha-blockers (doxazosin) due the pheochromocytoma, and the treatment of the LVT were initiated. The patient had traumatic abdominal bleeding, which confounded the treatment of LVT with anticoagulation. After careful consideration, the LVT was treated with the low molecular weight heparin dalteparine (5000E mane 7500E nocte sc daily) for 3 weeks followed by enoxaparine (10,000E sc daily) for another 7 weeks. The left ventricular function was normalized, and the left ventricular thrombus was dissolved after a few weeks. The pheochromocytoma was resected successfully with open left adrenalectomy 5 weeks later after treatment with alpha- (doxazosin initiated at 4 mg daily from the suspicion of pheochromocytoma and then slowly up-titrated to 8 mg bd) and beta-blockers (bisoprolol 2.5 mg daily from the diagnosis of TS). Histology revealed a radically extirpated pheochromocytoma. Genetic testing could not demonstrate any familial syndrome. At follow-up 3 months later, the blood pressure was 125/70 without any medications and plasma glucose levels had normalized.
Literature
Metadata
Title
Stumbling broke the spleen and unveiled pheochromocytoma, which in turn broke the heart
Authors
Shams Y-Hassan
Henrik Falhammar
Publication date
01-03-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02169-4

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine